Pharmaceuticals, Biotechnology and Life Sciences
Incyte has treated first vitiligo patient in its phase 3 clinical trial testing ruxolitinib cream as a monotherapy for older patients older than 12.
Enanta’s study has met its primary endpoint, as ALT reduction at week 12, was met in the 2.5mg dosing group in testing its lead FXR agonist, EDP-305 for treatment of NASH, also meeting key secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, in the 2.5mg dosing group.
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…
CINCINNATI–(BUSINESS WIRE)–Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2019 financial results after…
HAMILTON, Ontario–(BUSINESS WIRE)–#ABI–VoxNeuro is excited to announce that the company will receive up to CA$249,000 in research and development funding…
The trial is one of the first CAR T cell trials nationwide to enroll prostate cancer patients DUARTE, Calif.–(BUSINESS WIRE)–#CityofHope—City…
GW Pharmaceuticals paved a way to launch Epidyolex in Europe, for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.
Roche will present a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
Infiniti Research has recently completed its latest competitive intelligence engagement for a pharmaceutical logistics company, helping the client to enhance their accuracy in demand forecasting by 15%.